Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 96 Präparate · 6744 Quellenpassagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.3 · PDF-Seite 6
HOS-089601 · Präparat HOS-083891
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage 8cc0fe29768569a55e0703c8413d5a145077448bca5f7426ab9084406d167fa6 · Zeichen 0–91 im Abschnitt
Gegenanzeigen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.3 · PDF-Seite 6
HOS-089602 · Präparat HOS-083891
Known allergic reaction to hamster protein.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage 77517df52f2c6a3666f71d365e1d6bf0b36e7d15d9d92ae049ccc625385f41bc · Zeichen 93–136 im Abschnitt
Wechselwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 7
HOS-089603 · Präparat HOS-083891
No interactions of recombinant coagulation factor VIII products with other medicinal products have
been reported.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage ae4cb2e83deefafd1eaa5dbf632abbf053ca43e808aeacfd636ccaf9ad5571c3 · Zeichen 0–113 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 7
HOS-089604 · Präparat HOS-083891
Summary of the safety profile
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage d55a523b6a19085dba8d780d613791739571d7f51eec366b153cafd8949337ee · Zeichen 0–29 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 7
HOS-089605 · Präparat HOS-083891
Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the
infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea,
restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed
infrequently for ReFacto, and may in some cases progress to severe anaphylaxis including shock (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage 62cbe6683b4600bd0f03277db0a7b55c6463a9d19fe50bb718f1f96278934771 · Zeichen 31–446 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 7
HOS-089606 · Präparat HOS-083891
Trace amounts of hamster protein may be present in ReFacto AF. Very rarely, development of
antibodies to hamster protein has been observed, but there were no clinical sequelae. In a study of
ReFacto, twenty of 113 (18%) previously treated patients (PTPs) had an increase in anti-CHO
antibody titre, without any apparent clinical effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage 534fa711cf3d0541dcfd2f48a3b04e48dc3b1c980020a03abf6f3ebc26b0cddd · Zeichen 448–784 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 7–8
HOS-089607 · Präparat HOS-083891
7
Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated
with factor VIII, including with ReFacto AF. If such inhibitors occur, the condition may manifest itself
as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia
centre be contacted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage bf8ced2d78de8cdacbd5e49e6a6ce6ab4499ccc5ce8b1ef14566dcde2e6da667 · Zeichen 840–1171 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 8
HOS-089608 · Präparat HOS-083891
Tabulated list of adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage d51c90b617391dca447a849e03c6ddac1785fb6a36da5cf3e36f8f60e5aed8a9 · Zeichen 1173–1208 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 8
HOS-089609 · Präparat HOS-083891
The table presented below is according to the MedDRA system organ classification (SOC and
Preferred Term Level). Frequencies have been evaluated according to the following convention: very
common (≥ 1/10); common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1,000 to < 1/100). The table lists
adverse reactions reported in the clinical trials with ReFacto or ReFacto AF. The frequencies are based
on all causality treatment emergent adverse events in pooled clinical trials with 765 subjects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage c645a9f690da1de26afdb0335edba366ee51a6636c4951dc03bb5426db034b77 · Zeichen 1210–1695 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 8
HOS-089610 · Präparat HOS-083891
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage bf1e2ee6545f9f7e70d8b9c8e057ab316ed35a907cd5300a59dd41d8b91f5d64 · Zeichen 1697–1798 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 8
HOS-089611 · Präparat HOS-083891
System Organ Class Very common Common Uncommon
≥ 1/10 ≥ 1/100 ≥ 1/1,000 to
to < 1/10 < 1/100
Blood and lymphatic FVIII inhibition FVIII inhibition
system disorders (PUPs)* (PTPs)*
Immune system Anaphylactic reaction
disorders
Metabolism and Decreased appetite
nutrition disorders
Nervous system Headache Dizziness Neuropathy peripheral;
disorders somnolence; dysgeusia
Cardiac disorders Angina pectoris; tachycardia;
palpitations
Vascular disorders Haemorrhage; Hypotension; thrombophlebitis;
haematoma flushing
Respiratory, thoracic Cough Dyspnoea
and mediastinal
disorders
Gastrointestinal Diarrhoea; vomiting;
disorders abdominal pain; nausea
Skin and subcutaneous Urticaria; rash; pruritus Hyperhidrosis
tissue disorders
Musculoskeletal and Arthralgia Myalgia
connective tissue
disorders
General disorders and Pyrexia Chills; catheter site Asthenia; injection site reaction;
administration site related reaction injection site pain; injection site
conditions inflammation
Investigations Antibody test positive; Aspartate aminotransferase
Anti-factor VIII increased; alanine
antibody test positive aminotransferase increased;
blood bilirubin increased; blood
creatinine phosphokinase
increased
*
Frequency is based on studies with all FVIII products which included patients with severe
haemophilia A. PTPs = previously-treated patients, PUPs = previously-untreated patients
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage 706fe815ac2787c5e0817ec084895bb87e3f195532e8e5639c9c3f2f11cac918 · Zeichen 1801–4559 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 8
HOS-089612 · Präparat HOS-083891
Paediatric population
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage f8de81cbdc552a4640ef023d45d58925828891a0a998c10f0caafbd8351b3249 · Zeichen 4561–4582 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 8
HOS-089613 · Präparat HOS-083891
One event of cyst in an 11-year old patient and one event described as confusion in a 13-year old
patient have been reported as possibly related to ReFacto AF treatment
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage 53cc1dd2788f0849c857988b26154d4a6ca369ae30d6d45a5cbd49850ebd885e · Zeichen 4584–4752 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 8–9
HOS-089614 · Präparat HOS-083891
8
Safety of ReFacto AF was evaluated in studies that included both previously treated adults and
previously treated children and adolescents (n=18, aged 12-16 years in a study and n=49, aged 7-16
years in a supporting study), with a tendency for higher frequencies of adverse reactions in children
aged 7-16 years as compared to adults. Additional safety experience in children has been accrued
through studies that encompassed both previously treated (n=18 aged <6 years and n=19 aged 6 to
<12 years) and previously untreated (n=23 aged <6 years) patients and which supports a safety profile
similar with that observed in adult patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage 2c0c55bb4a7cbb86cd864f80b4cbbac0d6d9be47f9bbc2bdf717bd05952058a7 · Zeichen 4806–5445 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-089615 · Präparat HOS-083891
Reporting of suspected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage 822da43363cee11e87abeb55cf82453415269315377df150bb5de7dde8dd938f · Zeichen 5447–5487 im Abschnitt
Nebenwirkungen · ReFacto AF
ReFacto AF 250 IU powder and solvent for solution for injection ReFacto AF 500 IU powder and solvent for solution for injection ReFacto AF 1000 IU powder and solvent for solution for injection ReFacto AF 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-089616 · Präparat HOS-083891
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T15:12:00Z · SHA-256 8e1a3b6cc7bfba7f424249f78c7bab73f43a2b29dc7504859a655d85784fd1d6 · Passage 591ce3aa6d6555db7032d0551da929e990b92080da2928085827a75c666ec353 · Zeichen 5489–5803 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.